PainReform Ltd. (NASDAQ:PRFX) Sees Large Increase in Short Interest

PainReform Ltd. (NASDAQ:PRFX) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totalling 54,600 shares, a growth of 232.9% from the March 31st total of 16,400 shares. Based on an average trading volume of 135,900 shares, the short-interest ratio is currently 0.4 days. Approximately 3.0% of the shares of the stock are sold short.

PainReform Trading Down 3.5 %

PainReform stock opened at $0.81 on Friday. The firm has a 50 day simple moving average of $1.66 and a 200-day simple moving average of $2.12. PainReform has a 12-month low of $0.69 and a 12-month high of $26.41.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in PainReform stock. Armistice Capital LLC acquired a new stake in PainReform Ltd. (NASDAQ:PRFX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 170,000 shares of the company’s stock, valued at approximately $468,000. Armistice Capital LLC owned approximately 10.90% of PainReform at the end of the most recent reporting period. Institutional investors and hedge funds own 37.28% of the company’s stock.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.